Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors (usually asymptomatic)
Other diagnostic factors
- polyuria
- polydipsia
- fetal macrosomia in a previous pregnancy
Risk factors
- elevated BMI
- previous gestational diabetes
- previous macrosomic baby
- family history of diabetes mellitus
- non-white ancestry
- advanced maternal age (>40 years)
- polycystic ovarian syndrome (PCOS)
Diagnostic investigations
1st investigations to order
- oral glucose tolerance test
Investigations to consider
- random blood (plasma) glucose
- HbA1c
- fasting plasma glucose
Treatment algorithm
fasting plasma glucose ≥7 mmol/L (≥126 mg/dL), or 6 to 6.9 mmol/L (108-124 mg/dL) if large fetus/polyhydramnios
fasting plasma glucose <7 mmol/L (<126 mg/dL) without large fetus/polyhydramnios
labour
Contributors
Authors
Eleanor Scott, BM, BS, MD, FRCP
Professor of Medicine (Diabetes and Maternal Health)
Leeds Institute of Cardiovascular and Metabolic Medicine
Leeds Centre for Diabetes and Endocrinology
Leeds
UK
Disclosures
ES has received honoraria for talks given by Abbott Diabetes Care and Lilly Diabetes Care. ES has received research grant support from Abbott Diabetes Care in conjunction with the Medical Research Council (MRC) through an MRC industry collaboration agreement - this has gone directly to her University of Leeds employer.
Rebecca Spencer, MBChB, BSc, MRCOG, PhD
NIHR Clinical Lecturer in Obstetrics and Gynaecology
University of Leeds
Leeds
UK
Disclosures
RS is in receipt of a National Institute for Health and Care Research Clinical Lectureship and an Academy of Medical Sciences Starter Grant. RS has acted as an unpaid consultant to Comanche Biopharma, who are developing a novel therapy for pre-eclampsia.
Acknowledgements
Dr Scott and Dr Spencer would like to gratefully acknowledge Dr Ellen W. Seely, Dr Chloe Zera, Dr Jeremy Soule and Dr Leonard E. Egede, previous contributors to this topic.
Disclosures
EWS and CZ declare that they have no competing interests. JS has undertaken research support and speakers' bureau activity for Novartis, Bristol Myers Squibb, Astra Zeneca, and Sanofi-Aventis. LEE is an author of a number of references cited in this topic.
Peer reviewers
Helen Murphy, MBBch, BAO, FRACP, MD
Clinical Professor in Medicine (Diabetes and Antenatal Care)
University of East Anglia
Norwich
UK
Disclosures
HM sits on the Medtronic (insulin pump and CGM manufacturer) European scientific advisory board. HM has received research support (CGM sensors and insulin pumps) at reduced cost from Medtronic, Dexcom, and Johnson & Johnson. MH has contributed to educational events sponsored by NovoNordisk, Medtronic, Dexcom, and Abbott Diabetes Care.
Differentials
- Type 1 diabetes
- Type 2 diabetes
More DifferentialsGuidelines
- Standards of care in diabetes - 2023
- Diabetes in pregnancy: management from preconception to the postnatal period
More GuidelinesPatient information
Diabetes that develops in pregnancy (gestational diabetes)
Diabetes: what can I do to keep healthy?
More Patient information- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer